JP2007186518A5 - - Google Patents

Download PDF

Info

Publication number
JP2007186518A5
JP2007186518A5 JP2007031781A JP2007031781A JP2007186518A5 JP 2007186518 A5 JP2007186518 A5 JP 2007186518A5 JP 2007031781 A JP2007031781 A JP 2007031781A JP 2007031781 A JP2007031781 A JP 2007031781A JP 2007186518 A5 JP2007186518 A5 JP 2007186518A5
Authority
JP
Japan
Prior art keywords
methyl
chlorophenyl
azetidin
difluorophenyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007031781A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007186518A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2007186518A publication Critical patent/JP2007186518A/ja
Publication of JP2007186518A5 publication Critical patent/JP2007186518A5/ja
Pending legal-status Critical Current

Links

JP2007031781A 2003-06-11 2007-02-13 置換3−アルキルおよび3−アルケニルアゼチジン誘導体 Pending JP2007186518A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47785003P 2003-06-11 2003-06-11
US60/477,850 2003-06-11

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2006533655A Division JP3939744B2 (ja) 2003-06-11 2004-06-09 置換3−アルキルおよび3−アルケニルアゼチジン誘導体

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011053759A Division JP2011144196A (ja) 2003-06-11 2011-03-11 置換3−アルキルおよび3−アルケニルアゼチジン誘導体

Publications (2)

Publication Number Publication Date
JP2007186518A JP2007186518A (ja) 2007-07-26
JP2007186518A5 true JP2007186518A5 (cg-RX-API-DMAC7.html) 2008-04-17

Family

ID=33551769

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2006533655A Expired - Fee Related JP3939744B2 (ja) 2003-06-11 2004-06-09 置換3−アルキルおよび3−アルケニルアゼチジン誘導体
JP2007031781A Pending JP2007186518A (ja) 2003-06-11 2007-02-13 置換3−アルキルおよび3−アルケニルアゼチジン誘導体
JP2011053759A Withdrawn JP2011144196A (ja) 2003-06-11 2011-03-11 置換3−アルキルおよび3−アルケニルアゼチジン誘導体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2006533655A Expired - Fee Related JP3939744B2 (ja) 2003-06-11 2004-06-09 置換3−アルキルおよび3−アルケニルアゼチジン誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011053759A Withdrawn JP2011144196A (ja) 2003-06-11 2011-03-11 置換3−アルキルおよび3−アルケニルアゼチジン誘導体

Country Status (20)

Country Link
US (2) US7485732B2 (cg-RX-API-DMAC7.html)
EP (1) EP1636181A1 (cg-RX-API-DMAC7.html)
JP (3) JP3939744B2 (cg-RX-API-DMAC7.html)
KR (1) KR20060019587A (cg-RX-API-DMAC7.html)
CN (1) CN1802351A (cg-RX-API-DMAC7.html)
AU (1) AU2004252109B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0411131A (cg-RX-API-DMAC7.html)
CA (1) CA2527933C (cg-RX-API-DMAC7.html)
CO (1) CO5650244A2 (cg-RX-API-DMAC7.html)
EC (1) ECSP056207A (cg-RX-API-DMAC7.html)
IL (1) IL172417A0 (cg-RX-API-DMAC7.html)
IS (1) IS8146A (cg-RX-API-DMAC7.html)
MA (1) MA27847A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA05013583A (cg-RX-API-DMAC7.html)
NO (1) NO20060141L (cg-RX-API-DMAC7.html)
NZ (1) NZ543451A (cg-RX-API-DMAC7.html)
RU (1) RU2006100298A (cg-RX-API-DMAC7.html)
UA (1) UA83230C2 (cg-RX-API-DMAC7.html)
WO (1) WO2005000809A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200509019B (cg-RX-API-DMAC7.html)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003077847A2 (en) 2002-03-12 2003-09-25 Merck & Co., Inc. Substituted amides
ATE375349T1 (de) 2002-08-02 2007-10-15 Merck & Co Inc Substituierte furo(2,3-b)pyridin derivate
WO2004058145A2 (en) 2002-12-19 2004-07-15 Merck & Co., Inc. Substituted amides
JP3939744B2 (ja) 2003-06-11 2007-07-04 メルク エンド カムパニー インコーポレーテッド 置換3−アルキルおよび3−アルケニルアゼチジン誘導体
CA2543882A1 (en) 2003-10-30 2005-05-19 Merck & Co., Inc. Aralkyl amines as cannabinoid receptor modulators
JP2008540426A (ja) * 2005-05-02 2008-11-20 メルク エンド カムパニー インコーポレーテッド 糖尿病及び肥満の治療のためのジペプチジルペプチダーゼiv阻害薬及びカンナビノイドcb1受容体拮抗薬の組み合わせ
CA2624030A1 (en) 2005-09-29 2007-04-12 Tianying Jian Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
US7906652B2 (en) 2005-11-28 2011-03-15 Merck Sharp & Dohme Corp. Heterocycle-substituted 3-alkyl azetidine derivatives
AR058199A1 (es) * 2005-11-28 2008-01-23 Merck & Co Inc Derivados de 3- alquilazetidina sustituidos con heterociclos
DOP2006000273A (es) * 2005-12-08 2007-10-15 Aventis Pharma Inc Uso de un antagonista de cb1 para tratar efectos secundarios y sintomas negativos de la esquizofrenia
EP1991574B1 (en) 2006-02-22 2016-10-12 Merck Sharp & Dohme Corp. Oxyntomodulin derivatives
MX2009001043A (es) 2006-08-08 2009-02-06 Sanofi Aventis Imidazolidina-2,4-dionas sustituidas con arilaminoarilalquilo, procedimiento para preparalas, medicamentos que comprenden estos compuestos y su uso.
CA2664113C (en) 2006-09-22 2013-05-28 Merck & Co., Inc. Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer
WO2008118141A2 (en) * 2006-10-17 2008-10-02 Acadia Pharmaceuticals Inc. Use of cannabinoid modulating compounds in combination with other therapeutic compounds for adjunctive therapy
US7999107B2 (en) 2007-01-31 2011-08-16 Merck Sharp & Dohme Corp. Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators
EP2145884B1 (en) 2007-04-02 2014-08-06 Msd K.K. Indoledione derivative
WO2008156721A1 (en) 2007-06-20 2008-12-24 Merck & Co., Inc. Diphenyl substituted alkanes
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2212313A2 (en) * 2007-10-24 2010-08-04 Merck Sharp & Dohme Corp. Synthesis and crystalline forms of cb-1 antagonist/inverse agonist
EP2095814A1 (de) * 2008-02-26 2009-09-02 Wolfgang J. Kox Medikamentengestützter Nikotinentzug
EP2310372B1 (en) 2008-07-09 2012-05-23 Sanofi Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010039789A1 (en) 2008-10-03 2010-04-08 Schering Corporation Spiro-imidazolone derivatives as glucagon receptor antagonists
CA2741125A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
KR101320245B1 (ko) 2008-10-30 2013-10-30 머크 샤프 앤드 돔 코포레이션 이소니코틴아미드 오렉신 수용체 길항제
US8329914B2 (en) 2008-10-31 2012-12-11 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
US8470773B2 (en) 2009-06-12 2013-06-25 Merck Sharp & Dohme Corp. Thiophenes as glucagon receptor antagonists, compositions, and methods for their use
US8785608B2 (en) 2009-08-26 2014-07-22 Sanofi Crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
CA2786314A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2011140296A1 (en) 2010-05-05 2011-11-10 Infinity Pharmaceuticals Triazoles as inhibitors of fatty acid synthase
EP3159331A1 (en) 2010-05-05 2017-04-26 Infinity Pharmaceuticals, Inc. Tetrazolones as inhibitors of fatty acid synthase
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
EP3243385B1 (en) 2011-02-25 2021-01-13 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
US8846666B2 (en) 2011-03-08 2014-09-30 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120057A1 (de) 2011-03-08 2012-09-13 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683702B1 (de) 2011-03-08 2014-12-24 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8809325B2 (en) 2011-03-08 2014-08-19 Sanofi Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
KR101273566B1 (ko) 2011-09-05 2013-06-11 한국과학기술연구원 신규한 아제티딘 유도체 및 이를 함유하는 항우울제 조성물
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
RU2015106909A (ru) 2012-08-02 2016-09-27 Мерк Шарп И Доум Корп. Антидиабетические трициклические соединения
WO2017034872A1 (en) * 2015-08-25 2017-03-02 Janssen Pharmaceutica Nv Indazole derivatives useful as cb-1 inverse agonists
KR102405278B1 (ko) 2016-04-22 2022-06-07 악셀레론 파마 인코포레이티드 Alk7 결합 단백질 및 이들의 용도
KR20210090609A (ko) 2018-08-20 2021-07-20 베서, 파마 엘엘씨 공지된 신규 칸나비노이드의 응용
WO2020167706A1 (en) 2019-02-13 2020-08-20 Merck Sharp & Dohme Corp. 5-alkyl pyrrolidine orexin receptor agonists
US12331018B2 (en) 2019-02-13 2025-06-17 Merck Sharp & Dohme Llc Pyrrolidine orexin receptor agonists
EP4010314B1 (en) 2019-08-08 2024-02-28 Merck Sharp & Dohme LLC Heteroaryl pyrrolidine and piperidine orexin receptor agonists
US20230365533A1 (en) 2020-08-18 2023-11-16 Merck Sharp & Dohme Llc Bicycloheptane pyrrolidine orexin receptor agonists

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4052383A (en) 1974-10-30 1977-10-04 Schering Corporation N-diphenylalkyl-2-benzyl azacyclic compounds
US4133881A (en) * 1977-04-27 1979-01-09 A. H. Robins Company, Incorporated Azetidinyl acetonitrile and acetamide antiarrhythmia compositions and methods
US4242261A (en) * 1979-07-19 1980-12-30 A. H. Robins Company, Inc. Production of methylene-cycloamines
AU723349B2 (en) 1996-06-07 2000-08-24 Nps Pharmaceuticals, Inc. Coumpounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
WO1999004794A1 (en) 1997-07-25 1999-02-04 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
IL141769A0 (en) 1998-09-11 2002-03-10 Aventis Pharma Sa Azetidine derivatives, preparation and medicines containing them
FR2783246B1 (fr) 1998-09-11 2000-11-17 Aventis Pharma Sa Derives d'azetidine, leur preparation et les medicaments les contenant
EP1187810A2 (en) 1999-05-25 2002-03-20 Sepracor, Inc. Heterocyclic analgesic compounds and their use
US6635661B2 (en) 2000-05-25 2003-10-21 Sepracor Inc. Heterocyclic analgesic compounds and methods of use thereof
WO2001064676A2 (en) 2000-02-28 2001-09-07 Scios, Inc. INHIBITORS OF p38-α KINASE
US6479479B2 (en) * 2000-03-03 2002-11-12 Aventis Pharma S.A. Azetidine derivatives, their preparation and pharmaceutical compositions containing them
FR2805817B1 (fr) 2000-03-03 2002-04-26 Aventis Pharma Sa Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation
FR2805818B1 (fr) * 2000-03-03 2002-04-26 Aventis Pharma Sa Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant
FR2805810B1 (fr) 2000-03-03 2002-04-26 Aventis Pharma Sa Compositions pharmaceutiques contenant des derives de 3- amino-azetidine, les nouveaux derives et leur preparation
US6355631B1 (en) 2000-03-03 2002-03-12 Aventis Pharma S.A. Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and their preparation
GB0019006D0 (en) 2000-08-04 2000-09-20 Astrazeneca Ab Novel compounds
FR2814678B1 (fr) 2000-10-04 2002-12-20 Aventis Pharma Sa Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite
GB0117387D0 (en) 2001-07-17 2001-09-05 Novartis Ag Organic compounds
FR2829027A1 (fr) 2001-08-29 2003-03-07 Aventis Pharma Sa Association avec un antagoniste du recepteur cb1, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de parkinson
FR2829028B1 (fr) 2001-08-29 2004-12-17 Aventis Pharma Sa Association d'un antagoniste du recepteur cb1 et d'un produit qui active la neurotransmission dopaminergique dans le cerveau, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de
ES2282731T3 (es) 2002-12-23 2007-10-16 Janssen Pharmaceutica N.V. Derivados de 1-piperidin-4-il-4-azetidin-3-il-piperazina sustituida y su uso como antagonistas de neuroquininas.
US7504522B2 (en) 2003-05-01 2009-03-17 Vernalis Research Limited Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disorders
US20070173486A1 (en) 2003-05-01 2007-07-26 Vernalis Research Limited Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disordrs
JP3939744B2 (ja) 2003-06-11 2007-07-04 メルク エンド カムパニー インコーポレーテッド 置換3−アルキルおよび3−アルケニルアゼチジン誘導体
JP2007522255A (ja) 2004-02-17 2007-08-09 ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ 置換アゼチジン化合物、その製造および医薬品としての使用
US7906652B2 (en) * 2005-11-28 2011-03-15 Merck Sharp & Dohme Corp. Heterocycle-substituted 3-alkyl azetidine derivatives

Similar Documents

Publication Publication Date Title
JP2007186518A5 (cg-RX-API-DMAC7.html)
RU2006100298A (ru) Замещенные производные 3-алкил-и 3-алкенилазетидинов
RU2440330C2 (ru) ПРОИЗВОДНЫЕ 4-(2-АМИНО-1-ГИДРОКСИЭТИЛ)ФЕНОЛА, КАК АГОНИСТЫ β2 АДРЕНЕРГИЧЕСКОГО РЕЦЕПТОРА
RU2361860C2 (ru) Новые замещенные 3-сера-индолы
JP4568113B2 (ja) Mch調節作用を有するジアリール置換環状尿素誘導体
US20090023791A1 (en) PH-dependent NMDA receptor antagonists
JP6276760B2 (ja) 4−アルキニルイミダゾール誘導体およびそれを有効成分として含有する医薬
EA009732B1 (ru) Диарильные и арилгетероарильные производные мочевины в качестве модуляторов 5-ht-рецептора серотонина, пригодные для профилактики и лечения связанных с ним заболеваний
RU2007101236A (ru) Новые гидантоиновые производные для лечения обструктивных заболеваний дыхательных путей
JP2006525298A5 (cg-RX-API-DMAC7.html)
RU2003119548A (ru) Фенилэтенил-или фенилэтенилпроизводные в качестве антагонистов глутаматного рецептора
JP2010533715A5 (cg-RX-API-DMAC7.html)
JP2010505832A5 (cg-RX-API-DMAC7.html)
EA006583B1 (ru) Производные азетидина, способ их получения и содержащие их фармацевтические композиции
PT1542678E (pt) Derivados de 1h-1,2,4-triazol-3-carboxamida como ligandos de receptor de canabinóide-cb1
JP2008502614A5 (cg-RX-API-DMAC7.html)
JP2007522210A5 (cg-RX-API-DMAC7.html)
JP2007509959A (ja) トリアゾール化合物およびそれに関連する使用法
AU2002250256A1 (en) pH-dependent NMDA receptor antagonists
TW297813B (cg-RX-API-DMAC7.html)
JP2019537603A5 (cg-RX-API-DMAC7.html)
JP2005506292A5 (cg-RX-API-DMAC7.html)
RU2507200C2 (ru) Производные феноксихроманкарбоновой кислоты, замещенные в 6-ом положении
NZ525330A (en) Substituted 2-phenylaminoimidazoline phenyl ketone derivatives as IP antagonists
WO2019152536A1 (en) Inhibitors of the wnt/beta-catenin pathway